0.00Open0.22Pre Close0 Volume68 Open Interest5.00Strike Price0.00Turnover349.06%IV155.88%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.22Extrinsic Value100Contract SizeAmericanOptions Type0.2878Delta0.1880Gamma9.27Leverage Ratio-0.0131Theta0.0002Rho2.67Eff Leverage0.0018Vega
LAVA Therapeutics Stock Discussion
LAVA Therapeutics N.V., a leader in the biotechnology sector, has recently announced a significant clinical development milestone achieved by Pfizer for the drug PF-08046052. This milestone has prompted the first payment of $7 million to LAVA, marking a notable event in the field of immuno-oncology. $LAVA Therapeutics(LVTX.US)$
https://stockregion.app/p/biotech-leader-announces-7m-milestone
No comment yet